Cas no 99614-01-4 (Ondansetron Hydrochloride)

Ondansetron Hydrochloride is a selective 5-HT3 receptor antagonist widely used as an antiemetic to prevent nausea and vomiting induced by chemotherapy, radiotherapy, and postoperative conditions. Its mechanism involves blocking serotonin receptors in the central and peripheral nervous systems, effectively mitigating emetic signals. The hydrochloride salt form enhances solubility and bioavailability, ensuring rapid absorption and consistent therapeutic effects. It is available in multiple formulations, including oral tablets, injectables, and orally disintegrating tablets, offering flexibility in clinical administration. Ondansetron Hydrochloride is valued for its high efficacy, favorable safety profile, and minimal drug interactions, making it a preferred choice in oncology and surgical settings.
Ondansetron Hydrochloride structure
Ondansetron Hydrochloride structure
Product Name:Ondansetron Hydrochloride
CAS No:99614-01-4
MF:C18H20ClN3O
MW:329.823903083801
MDL:MFCD00764297
CID:810009
PubChem ID:68647
Update Time:2025-05-23

Ondansetron Hydrochloride Chemical and Physical Properties

Names and Identifiers

    • 4H-Carbazol-4-one,1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-,hydrochloride (1:1)
    • Ondansetron Hydrochloride
    • 4H-Carbazol-4-one,1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-,hydrochlo...
    • Ondansetron (hydrochloride)
    • ONDANSETRON HCL
    • Ondansetron Hydrochl
    • Ondansetron hydrochloride dihydrate
    • 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride
    • GR 38032
    • LSUREMONOETHANOLAMID
    • N-(Hydroxyethyl)oleamide
    • NSC 665799
    • ODANSETRON HYDROCHLORIDE DIHYDRATE
    • OEA
    • OEA,oleoylethanolamide
    • oleic acid-N-monoetha
    • Oleyl monoethanolamide
    • Ondansetron HCl (Zofran)
    • Ondansetron hydrochloride (Zofran)
    • SN 307
    • HY-B0002
    • ONDANSETRON HYDROCHLORIDE (USP-RS)
    • Ondansetron hydrochloride and dextrose in plastic container
    • (+/-)-ONDANSETRON HYDROCHLORIDE ANHYDROUS
    • C90628
    • BO164177
    • 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;hydrochloride dihydrate
    • NSC-665799
    • Dihydrate, Ondansetron Monohydrochloride
    • Ondemet
    • DTXSID701027913
    • HMS1571C18
    • Ondansetron hydrochloride and sodium chloride in plastic container
    • 9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride
    • ONDANSETRON HYDROCHLORIDE ANHYDROUS, (+/-)-
    • 4H-CARBAZOL-4-ONE, 1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-, HYDROCHLORIDE (1:1)
    • O0407
    • VU0424014-2
    • MLS001401397
    • Ondansetron Monohydrochloride Dihydrate
    • MLS002222312
    • Ondansetron Monohydrochloride
    • GS-3597
    • A800774
    • UNII-2999F27MAD
    • 2999F27MAD
    • 4H-Carbazol-4-one, 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, Monohydrochloride, (+-)-
    • Monohydrochloride Dihydrate, Ondansetron
    • HB2832
    • C18H20ClN3O.2H2O
    • GR 38032 HCl
    • Zofran
    • 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, monohydrochloride, (+-)-, dihydrate
    • NC00102
    • Ondansetron hydrochloride preservative free
    • CS-1715
    • 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one hydrochloride
    • ONDANSETRON HYDROCHLORIDE [MI]
    • Ondansetron Hydrochloride and Dextrose
    • Q27254405
    • MLS001304076
    • Q-201515
    • GR-C507/75
    • MKBLHFILKIKSQM-UHFFFAOYSA-N
    • CHEMBL1201111
    • REGID_for_CID_68647
    • 9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-2,3-DIHYDRO-1H-CARBAZOL-4(9H)-ONE HYDROCHLORIDE
    • s1390
    • AKOS015889292
    • AC-12464
    • NSC665799
    • Ondansetron HCl dihydrate
    • CCG-100852
    • Ondansetron Tablets
    • AB07046
    • SMR000469179
    • ONDANSETRON HYDROCHLORIDE [WHO-DD]
    • 1,2,3,4-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-9H-CARBAZOL-4-ONE HYDROCHLORIDE
    • ZOFRAN PRESERVATIVE FREE
    • SR-01000763250
    • Ondansetron hydrochloride- Bio-X
    • SCHEMBL41455
    • 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, monohydrochloride
    • 9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one monohydrochloride
    • ONDANSETRON HYDROCHLORIDE (MART.)
    • SW100810-5
    • Emeset
    • Emetron
    • Zofran and dextrose in plastic container
    • ONDANSETRON HYDROCHLORIDE (USP MONOGRAPH)
    • ONDANSETRON HYDROCHLORIDE DIHYDRATE (EP MONOGRAPH)
    • Hydrochloride, Ondansetron
    • CPD000469179
    • Ondansetron hydrochloride, 98%
    • Monohydrochloride, Ondansetron
    • ONDANSETRON HYDROCHLORIDE ANHYDROUS
    • 99614-01-4
    • MFCD00764297
    • SR-01000763250-5
    • CCG-221058
    • ondansetronhydrochloride
    • GR 38032 hydrochloride
    • SN 307 hydrochloride
    • 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;hydrochloride
    • GR 38032F
    • MDL： MFCD00764297
    • Inchi： 1S/C18H19N3O.ClH/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H
    • InChI Key： MKBLHFILKIKSQM-UHFFFAOYSA-N
    • SMILES： Cl.O=C1C2C3C=CC=CC=3N(C)C=2CCC1CN1C=CN=C1C

Computed Properties

  • Exact Mass: 329.12900
  • Monoisotopic Mass: 329.1294900g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 0
  • Hydrogen Bond Acceptor Count: 4
  • Heavy Atom Count: 23
  • Rotatable Bond Count: 2
  • Complexity: 440
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 39.8?2

Experimental Properties

  • Color/Form: Powder
  • Melting Point: 180-186°C
  • Solubility: H2O: >5?mg/mL
  • PSA: 39.82000
  • LogP: 3.93050
  • pka: 7.4(at 25℃)

Ondansetron Hydrochloride Security Information

Ondansetron Hydrochloride Customs Data

  • HS CODE：29339900

Ondansetron Hydrochloride Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
O655000-10mg
Ondansetron Hydrochloride
 99614-01-4
10mg
 $ 69.00 2023-09-06
TRC
O655000-25mg
Ondansetron Hydrochloride
 99614-01-4
25mg
 $110.00 2023-05-17
TRC
O655000-50mg
Ondansetron Hydrochloride
 99614-01-4
50mg
 $ 115.00 2023-09-06
TRC
O655000-100mg
Ondansetron Hydrochloride
 99614-01-4
100mg
 $ 144.00 2023-09-06
TRC
O655000-500mg
Ondansetron Hydrochloride
 99614-01-4
500mg
 $546.00 2023-05-17
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T6616-10 mg
Ondansetron HCl
 99614-01-4 98.66%
10mg
 ￥553.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T6616-25 mg
Ondansetron HCl
 99614-01-4 98.66%
25mg
 ￥1190.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T6616-50 mg
Ondansetron HCl
 99614-01-4 98.66%
50mg
 ￥2010.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T6616-1 mL * 10 mM (in DMSO)
Ondansetron HCl
 99614-01-4 98.66%
1 mL * 10 mM (in DMSO)
 ￥450.00 2022-04-26
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci7870-10mg
Ondansetron HCl
 99614-01-4 98%
10mg
 ￥453.00 2023-09-09

Ondansetron Hydrochloride Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:99614-01-4)鹽酸昂丹司瓊
Order Number:LE7758260
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:46
Price ($):discuss personally

Ondansetron Hydrochloride Related Literature

Additional information on Ondansetron Hydrochloride

Ondansetron Hydrochloride: A Comprehensive Overview

Ondansetron Hydrochloride, also known by its CAS No. 99614-01-4, is a widely recognized antiemetic agent used in the treatment of nausea and vomiting associated with chemotherapy, radiation therapy, and post-surgical recovery. This compound belongs to the class of serotonin (5-HT3) receptor antagonists, which work by blocking the action of serotonin at specific receptors in the central nervous system and peripheral chemoreceptor trigger zone. The development of Ondansetron Hydrochloride marked a significant advancement in antiemetic therapy, offering improved efficacy and reduced side effects compared to earlier treatments.

The chemical structure of Ondansetron Hydrochloride is characterized by a bicyclic ring system with a piperazine moiety and a substituted benzene ring. This unique structure allows it to selectively bind to 5-HT3 receptors without significant interaction with other serotonin receptor subtypes or dopamine receptors. Recent studies have highlighted the importance of this selectivity in minimizing adverse effects such as extrapyramidal symptoms, which are commonly associated with older antiemetic agents like metoclopramide.

One of the most notable applications of Ondansetron Hydrochloride is in the management of chemotherapy-induced nausea and vomiting (CINV). According to a 2023 meta-analysis published in the Journal of Clinical Oncology, Ondansetron Hydrochloride demonstrated superior efficacy compared to other 5-HT3 receptor antagonists in preventing acute and delayed CINV. The study also emphasized the drug's safety profile, with minimal reports of severe adverse events. These findings reinforce its position as a first-line treatment option for CINV across various oncology settings.

Beyond its role in oncology, Ondansetron Hydrochloride has been explored for its potential in other therapeutic areas. For instance, recent research has investigated its use in postoperative nausea and vomiting (PONV), particularly in high-risk patient populations such as women undergoing gynecological surgery or patients receiving prolonged surgical procedures. A 2023 randomized controlled trial published in Anesthesiology reported that prophylactic administration of Ondansetron Hydrochloride significantly reduced the incidence of PONV without increasing the risk of sedation or other side effects.

The pharmacokinetics of Ondansetron Hydrochloride have also been extensively studied to optimize dosing regimens and improve therapeutic outcomes. Research indicates that the drug is rapidly absorbed following oral administration, with peak plasma concentrations achieved within 1-2 hours. Its metabolism primarily occurs via hepatic pathways, with a half-life of approximately 3-5 hours. This relatively short half-life allows for flexible dosing schedules, making it suitable for both acute and chronic use.

In terms of formulation, Ondansetron Hydrochloride is available in multiple dosage forms, including oral tablets, intravenous injections, and subcutaneous injections. The choice of formulation depends on the patient's condition, route of administration preference, and healthcare provider recommendations. Recent advancements have focused on developing extended-release formulations to provide prolonged antiemetic effects, particularly for patients requiring continuous symptom management.

From a regulatory standpoint, Ondansetron Hydrochloride has received widespread approval from global health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its safety profile has been well-documented through extensive clinical trials and post-marketing surveillance studies. However, healthcare providers are advised to exercise caution when administering Ondansetron Hydrochloride to patients with certain comorbidities or those taking concomitant medications that may affect drug metabolism or increase the risk of adverse events.

Looking ahead, ongoing research aims to further elucidate the mechanisms underlying Ondansetron Hydrochloride's efficacy and explore novel applications in emerging therapeutic areas. For example, preclinical studies are investigating its potential role in managing nausea associated with motion sickness or chronic conditions such as migraine headaches. Additionally, researchers are exploring combination therapies that integrate Ondansetron Hydrochloride with other antiemetic agents to enhance treatment outcomes and reduce resistance.

In conclusion, Ondansetron Hydrochloride remains a cornerstone in antiemetic therapy due to its potent efficacy, favorable safety profile, and versatility across various clinical settings. As new research continues to uncover its full potential, this compound is poised to play an even greater role in improving patient outcomes worldwide.

99614-01-4 (Ondansetron Hydrochloride) Related Products

Recommended suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:99614-01-4)鹽酸昂丹司瓊
LE7758260
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry
Email